D-0018-2021 Class II Terminated

Recalled by Direct Rx — Dawsonville, GA

FDA drug recall D-0018-2021 was initiated by Direct Rx on Apr 30, 2019 and is designated Class II. Reason for recall: CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level per manufacturer The recall status is terminated (terminated Dec 4, 2020). Affected quantity: 33 bottles.

Recall details

Product Type
Drugs
Report Date
Oct 14, 2020
Initiation Date
Apr 30, 2019
Termination Date
Dec 4, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
33 bottles

Product description

Losartan Potassium 100 mg, 30 Tabs bottles, Rx only, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534 NDC 61919-952-30

Reason for recall

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level per manufacturer

Distribution pattern

GA

Code information

Lot: 27AU1801 Exp. 02/28/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0018-2021
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0018-2021. Report a data issue: hello@regdatalab.com.